I 
119TH CONGRESS 
1ST SESSION H. R. 3375 
To require that the retail list price for certain prescription drugs and biologi-
cal products may not exceed the average retail list price for the drug 
or biological product among certain nations. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 13, 2025 
Mr. VAN DREW introduced the following bill; which was referred to the 
Committee on Energy and Commerce 
A BILL 
To require that the retail list price for certain prescription 
drugs and biological products may not exceed the average 
retail list price for the drug or biological product among 
certain nations. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Fair Prescription Drug 
Prices for Americans Act’’. 
VerDate Sep 11 2014 
21:17 May 19, 2025
Jkt 059200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H3375.IH
H3375
kjohnson on DSK7ZCZBW3PROD with $$_JOB
SEC. 2. INTERNATIONAL REFERENCE PRICING FOR PRE-
SCRIPTION DRUGS AND BIOLOGICAL PROD-
UCTS. 
(a) DEFINITIONS.—In this section: 
(1) BIOLOGICAL PRODUCT.—The term ‘‘biologi-
cal product’’ means a biological product licensed 
under subsection (a) or (k) of section 351 of the 
Public Health Service Act (42 U.S.C. 262). 
(2) DRUG.—The term ‘‘drug’’ means a drug ap-
proved under subsection (c) or (j) of section 505 of 
the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 355). 
(3) SECRETARY.—The term ‘‘Secretary’’ means 
the Secretary of Health and Human Services. 
(b) CAP ON RETAIL LIST PRICE OF PRESCRIPTION 
DRUGS
AND BIOLOGICAL PRODUCTS.—The retail list 
price in the United States for a drug or a biological prod-
uct may not exceed the average retail list price for the 
drug or biological product among Canada, France, Ger-
many, Italy, Japan, and the United Kingdom, as cal-
culated under subsection (c). 
(c) CALCULATION
OF
AVERAGE
RETAIL
LIST 
PRICE.—The Secretary shall calculate on an annual basis 
the average retail list price for each drug and biological 
product sold in Canada, France, Germany, Italy, Japan, 
and the United Kingdom, through a combination of data 
VerDate Sep 11 2014 
21:17 May 19, 2025
Jkt 059200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H3375.IH
H3375
kjohnson on DSK7ZCZBW3PROD with $$_JOB
reported by manufacturers of drugs and biological prod-
ucts under subsection (e) and data obtained through re-
view of publicly filed materials by manufacturers of drugs 
and biological products in such countries. 
(d) CIVIL MONETARY PENALTY.— 
(1) IN GENERAL.—Any manufacturer that vio-
lates subsection (b) with respect to a drug or biologi-
cal product shall be subject to a civil monetary pen-
alty imposed by the Secretary in amount equal to 
the product obtained by multiplying— 
(A) the difference between— 
(i) the list price for the drug or bio-
logical product sold in the United States; 
and 
(ii) the average retail list price for the 
drug or biological product sold in Canada, 
France, Germany, Italy, Japan, and the 
United Kingdom, as calculated under sub-
section (c); and 
(B) 10. 
(2) REQUIREMENT.—The amount of a civil 
monetary penalty under paragraph (1) shall be cal-
culated and charged for each unit of drug or biologi-
cal product sold. 
VerDate Sep 11 2014 
21:17 May 19, 2025
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H3375.IH
H3375
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(e) DATA COLLECTION.—Each manufacturer of a 
drug or biological product shall submit to the Secretary 
on an annual basis— 
(1) the list price for the drug or biological prod-
uct sold in the United States; and 
(2) the list price for the drug or biological prod-
uct sold in each of Canada, France, Germany, Italy, 
Japan, and the United Kingdom. 
(f) GUIDANCE AND REGULATIONS.—The Secretary 
shall issue guidance and promulgate regulations to imple-
ment this section. 
Æ 
VerDate Sep 11 2014 
21:17 May 19, 2025
Jkt 059200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6301
E:\BILLS\H3375.IH
H3375
kjohnson on DSK7ZCZBW3PROD with $$_JOB